References
- Haessler J, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin. Cancer Res. 2007;13:7073–7079.
- Brenner MK, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85–86.
- Stewart AK, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–3779.
- Moreau P, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731–735.
- Attal M, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294.
- McCarthy PL, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEJM. 2012;366:1770–1781.
- Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM. 2012;366:1782–1791
- Sonneveld P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. [Erratum appears in J Clin Oncol. 2012 Oct 10;30(29):3654]. J Clin Oncol. 2012;30:2946–2955.
- Krishnan A, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial. Lancet Oncol. 2011;12:1195–1203.
- Kapoor P, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31:4529–4535.